速递｜Nature头条：贺建奎前妻创办新公司，公开表示“CRISPR婴儿”时代或已来临

Core Insights - The article discusses the controversial topic of "CRISPR babies" and highlights the emergence of Cathy Tie, a biotech entrepreneur, who advocates for the consideration of gene editing in human embryos to prevent genetic diseases [2][8]. Company and Industry Summary - Cathy Tie, a Canadian entrepreneur, has founded multiple biotech companies over the past 11 years, including Locke Bio in 2020, which focuses on telemedicine and medical data mining services [4]. - Tie's latest venture, Manhattan Genomics, co-founded with Eriona Hysolli, aims to explore human embryo gene editing to prevent hereditary diseases [7][8]. - On the same day, another company, Preventive, announced nearly $30 million in funding to explore human embryo gene editing, indicating a growing interest in this controversial field [8]. - The scientific community generally views the commercialization of embryo gene editing as premature, citing significant safety and ethical concerns compared to existing CRISPR therapies approved for treating specific genetic disorders [8][9]. - CRISPR technology, awarded the Nobel Prize in Chemistry in 2020, is recognized as a revolutionary biotechnological advancement, yet the push for embryo editing has faced global condemnation and regulatory restrictions [9]. - Recent advancements in non-reproductive cell gene editing have been significant, with the first CRISPR-Cas9 therapy approved for hereditary blood disorders in 2023, showcasing the potential of gene editing while emphasizing the ethical divide between editing somatic and germline cells [9].